CGChristian Gulmann

Christian Gulmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christian Gulmann has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • A Grace

    Department of Pathology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland

    1 shared publication
  • D Butler

    Department of Pathology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland

    1 shared publication
  • E F Petricoin

    Center for Applied Proteomics and Molecular Medicine George Mason University Manassas VA USA

    1 shared publication
  • E Kay

    Department of Pathology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland

    1 shared publication
  • E W Kay

    Department of Pathology, Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland

    1 shared publication
  • G S Eichler

    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    1 shared publication

Latest Publications

  • If it's not CK5/6 positive, TTF‐1 negative it's not a squamous cell carcinoma of lung

    by Paul Downey, Robert Cummins, Margaret Moran, Christian Gulmann

    Novel targeted treatment of non‐small cell lung cancer (NSCLC) requires accurate classification of NSCLC as squamous cell carcinoma (SCC) and adenocarcinoma (AC). This study details the CK5/6 and TTF‐1 immunoprofile of surgical resections of 45 NSCLCs (24 ACs and 21 SCCs) in tissue microarrays. All SCCs were CK5/6 positive, TTF‐1 negative. 20 of 24 adenocarcinomas had the reverse pattern. In conclusion, all SCCs in this study were CK5/6 positive and TTF‐1 negative, and therefore tumours that do not display this phenotype are unlikely to be SCCs. CK5/6 and TTF‐1 is therefore a practical panel for the distinction between pulmonary SCC from AC in routine histopathology practice.


  • Open Access

    Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition

    by K M Sheehan, C Gulmann, G S Eichler, J N Weinstein, H L Barrett, E W Kay, R M Conroy, L A Liotta, E F Petricoin

    Molecular crosstalk, including reciprocal stimulation, is theorized to take place between epithelial cancer cells and surrounding non-neoplastic stromal cells. This is the rationale for stromal therapy, which could eliminate support of a cancer by its genetically stable stroma. Epithelial-stromal crosstalk is so far poorly documented in vivo, and cell cultures and animal experiments may not provide accurate models. The current study details stromal-epithelial signalling pathways in 35 human colon cancers, and compares them with matched normal tissues using quantitative proteomic microarrays. Lysates prepared from separately microdissected epithelium and stroma were analysed using antibodies against 61 cell signalling proteins, most of which recognize activated phospho-isoforms. Analyses using unsupervised and supervised statistical methods suggest that cell signalling pathway profiles in stroma and epithelium appear more similar to each other in tumours than in normal colon. This supports the concept that coordinated crosstalk occurs between epithelium and stroma in cancer and suggests epithelial-mesenchymal transition. Furthermore, the data herein suggest that it is driven by cell proliferation pathways and that, specifically, several key molecules within the mitogen-activated protein kinase pathway may play an important role. Given recent findings of epithelial-mesenchymal transition in therapy-resistant tumour epithelium, these findings could have therapeutic implications for colon cancer.


  • Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays

    by C Gulmann, D Butler, E Kay, A Grace, M Leader

    Aims:  Tissue microarrays offer an efficient way of examining a large number of tumour cases on a single glass slide. A major concern, however, is tumour heterogeneity. Also, the use of tissue microarrays in biopsy material is unexplored. The purpose of the present study was to assess the possibility and validity of arraying three 0.6‐mm cores per case in endoscopic gastric cancer biopsies for immunophenotyping.Methods and results:  Thirty‐eight cases were studied with immunohistochemical staining for p53, CD44v6 and vascular endothelial growth factor. Full tissue sections were compared with triple core‐tissue microarrays. Thirty‐six cases contained three cores with tumour, one case contained two cores with tumour and one case contained only a single core with viable tumour and was excluded. Three further cores had been lost from three separate cases on the sections for immunohistochemistry. κ values for whole‐sections versus tissue microarrays ranged between 0.77 and 0.94. p53 immunohistochemical staining (interpretation as + or –) yielded the best result with only 1/37 mismatches, whereas CD44v6 (graded both for intensity and extent) showed 3/37 mismatches. The small depth of tissue in cores from biopsies necessitates all cores being arrayed flush with the face of the recipient wax block for maximizing the number of sections available. Compared with the first section over 30 additional 4‐µm sections were available before the first case (with one core left) had to be excluded and 80 sections before half the tissue cores were lost.Conclusions:  It is impracticable to array more than 120–150 cores per block. Tissue microarray with three cores per case is feasible and valid for studying biopsy material.